(April 10, 2018) Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had at least a partial response to platinum based chemotherapy have a new, FDA approved option for maintenance therapy. The evidence that led to the FDA approving rucaparib comes from the phase 3 ARIEL3 clinical trial, which enrolled 564 patients. The trial showed a statistically significant difference between the drug and the placebo, regardless of BRCA status.
“Both the efficacy and safety results from the ARIEL3 study reinforce the important role of Rubraca (rucaparib) in the treatment of recurrent ovarian cancer and expands the treatment options for patients and physicians battling this disease,” states Robert Coleman, MD, one of the Principal Investigators on the trial at MD Anderson Cancer Center and an OCRFA scientific advisory committee member.
For more information from Clovis, such as side effects and study details, you can read the press release.
